帕金森病与丘脑底核脑深部电刺激:GBA突变携带者的认知影响
该研究比较帕金森病中GBA突变携带者与非携带者接受或不接受丘脑底核脑深部电刺激(STN-DBS)时认知下降速率的差异。分析12个数据集共366例受试者,纵向随访36-60个月。结果显示GBA突变合并STN-DBS者Mattis痴呆评定量表(MDRS)年下降幅度大于其他三组;作者建议DBS候选者筛查GBA突变并告知携带者相关风险。
要点
- GBA+DBS+者MDRS年下降较GBA-DBS-者多2.02分(95%CI -2.35至-1.69)。
- GBA+DBS+者MDRS年下降较GBA+DBS-者多1.71分(95%CI -2.14至-1.28)。
- 作者建议DBS候选者筛查GBA突变,并告知携带者STN-DBS相关潜在风险。
核心结论
- 尽管非随机,该复合分析提示GBA突变与STN-DBS的联合作用对认知有负面影响。
- 作者建议将GBA突变筛查纳入DBS术前决策过程。
- 作者建议告知GBA突变携带者STN-DBS相关的潜在风险,以便考虑替代方案。
研究设计与样本
- 检查12个数据集的临床与遗传数据,共366例受试者。
- 分为GBA+DBS+(58例)、GBA+DBS-(82例)、GBA-DBS+(98例)、GBA-DBS-(128例)。
- GBA突变携带者按突变严重程度分为风险变异、轻度、重度。
- 使用线性混合模型比较MDRS评分随时间的变化率。
- 纵向随访范围为术后36-60个月。
主要发现
- GBA+DBS+者MDRS评分平均每年较GBA-DBS-者多下降2.02分(95%CI -2.35至-1.69)。
- GBA+DBS+者MDRS评分平均每年较GBA+DBS-者多下降1.71分(95%CI -2.14至-1.28)。
- GBA+DBS+者MDRS评分平均每年较GBA-DBS+者多下降1.49分(95%CI -1.80至-1.18)。
临床怎么用
- 作者建议DBS候选者筛查GBA突变作为术前决策的一部分。
- 作者建议告知GBA突变携带者STN-DBS相关潜在风险,以便考虑替代方案。
局限性
- 原文指出该分析非随机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to compare the rate of change in cognition between glucocerebrosidase (GBA) mutation carriers and noncarriers with and without subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson disease. METHODS: Clinical and genetic data from 12 datasets were examined. Global cognition was assessed using the Mattis Dementia Rating Scale (MDRS). Subjects were examined for mutations in GBA and categorized as GBA carriers with or without DBS (GBA+DBS+, GBA+DBS-), and noncarriers with or without DBS (GBA-DBS+, GBA-DBS-). GBA mutation carriers were subcategorized according to mutation severity (risk variant, mild, severe). Linear mixed modeling was used to compare rate of change in MDRS scores over time among the groups according to GBA and DBS status and then according to GBA severity and DBS status. RESULTS: Data were available for 366 subjects (58 GBA+DBS+, 82 GBA+DBS-, 98 GBA-DBS+, and 128 GBA-DBS- subjects), who were longitudinally followed (range = 36-60 months after surgery). Using the MDRS, GBA+DBS+ subjects declined on average 2.02 points/yr more than GBA-DBS- subjects (95% confidence interval [CI] = -2.35 to -1.69), 1.71 points/yr more than GBA+DBS- subjects (95% CI = -2.14 to -1.28), and 1.49 points/yr more than GBA-DBS+ subjects (95% CI = -1.80 to -1.18). INTERPRETATION: Although not randomized, this composite analysis suggests that the combined effects of GBA mutations and STN-DBS negatively impact cognition. We advise that DBS candidates be screened for GBA mutations as part of the presurgical decision-making process. We advise that GBA mutation carriers be counseled regarding potential risks associated with STN-DBS so that alternative options may be considered. ANN NEUROL 2022;91:424-435.
引用
- Pal G, Mangone G, Hill EJ, et al. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022. PMID: 34984729. doi:10.1002/ana.26302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。